Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Core Viewpoint - Marker Therapeutics, Inc. has appointed Kathryn Penkus Corzo to its Board of Directors, effective November 1, 2025, to strengthen its leadership as it advances its clinical programs, particularly the APOLLO program for CAR-relapsed Diffuse Large B Cell Lymphoma (DLBCL) [1][4]. Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company based in Houston, TX, focusing on next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [6]. - The company was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [6]. Leadership Appointment - Kathryn Penkus Corzo brings over 30 years of experience in biopharma, including roles in R&D, clinical trials, regulatory approvals, and commercialization [2]. - Prior to joining Marker, she served as President and COO at bit.bio Ltd, where she expanded the company's product portfolio and established scalable operations [2]. - Corzo has held senior positions at Takeda Ventures, Sanofi Genzyme, Hoffmann-La Roche, Eli Lilly, and Syndax Pharmaceuticals, contributing to the development and launch of multiple global blockbuster cancer therapies [3]. Clinical Development Focus - Marker Therapeutics is committed to advancing its lead asset MT-601 and the APOLLO program, which targets CAR-relapsed DLBCL [4]. - The company emphasizes the potential of its Multi-Antigen Recognizing (MAR) T cell platform, which aims to address limitations of current treatments and improve clinical outcomes for patients with limited options [5]. MAR-T Cell Platform - The MAR-T cell platform is a novel, non-genetically modified cell therapy that selectively expands tumor-specific T cells capable of recognizing a broad range of tumor antigens [5]. - This approach allows recognition of hundreds of different epitopes within up to six tumor-specific antigens, potentially reducing the risk of tumor escape [5]. - Marker believes that its MAR-T cell products will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell therapies [5].